CN114916584A - Solid beverage for inhibiting activity of helicobacter pylori - Google Patents
Solid beverage for inhibiting activity of helicobacter pylori Download PDFInfo
- Publication number
- CN114916584A CN114916584A CN202210433316.4A CN202210433316A CN114916584A CN 114916584 A CN114916584 A CN 114916584A CN 202210433316 A CN202210433316 A CN 202210433316A CN 114916584 A CN114916584 A CN 114916584A
- Authority
- CN
- China
- Prior art keywords
- powder
- oligosaccharide
- helicobacter pylori
- solid beverage
- selenium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000590002 Helicobacter pylori Species 0.000 title claims abstract description 39
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 39
- 235000013361 beverage Nutrition 0.000 title claims abstract description 36
- 239000007787 solid Substances 0.000 title claims abstract description 36
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 49
- 235000011305 Capsella bursa pastoris Nutrition 0.000 claims abstract description 36
- 240000008867 Capsella bursa-pastoris Species 0.000 claims abstract description 36
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 27
- 239000011669 selenium Substances 0.000 claims abstract description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000006041 probiotic Substances 0.000 claims abstract description 24
- 235000018291 probiotics Nutrition 0.000 claims abstract description 24
- 239000002131 composite material Substances 0.000 claims abstract description 22
- 230000000694 effects Effects 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 241000283690 Bos taurus Species 0.000 claims abstract description 13
- OPSXJNAGCGVGOG-DKWTVANSSA-L Calcium L-aspartate Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CC([O-])=O OPSXJNAGCGVGOG-DKWTVANSSA-L 0.000 claims abstract description 13
- 229940034055 calcium aspartate Drugs 0.000 claims abstract description 13
- 210000003022 colostrum Anatomy 0.000 claims abstract description 13
- 235000021277 colostrum Nutrition 0.000 claims abstract description 13
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 13
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 13
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 13
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 13
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 13
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims abstract description 13
- 239000000832 lactitol Substances 0.000 claims abstract description 13
- 229960003451 lactitol Drugs 0.000 claims abstract description 13
- 235000010448 lactitol Nutrition 0.000 claims abstract description 13
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 13
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 13
- 235000008939 whole milk Nutrition 0.000 claims abstract description 13
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 18
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 18
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 17
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 9
- 241001608472 Bifidobacterium longum Species 0.000 claims description 9
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 9
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 9
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 9
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 9
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 9
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 9
- 244000199866 Lactobacillus casei Species 0.000 claims description 8
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 8
- 229940017800 lactobacillus casei Drugs 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000011812 mixed powder Substances 0.000 claims description 6
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 3
- 235000011152 sodium sulphate Nutrition 0.000 claims description 3
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 230000008029 eradication Effects 0.000 abstract description 9
- 238000002560 therapeutic procedure Methods 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 206010019375 Helicobacter infections Diseases 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019722 synbiotics Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- XSQUKJJJFZCRTK-OUBTZVSYSA-N Urea-13C Chemical compound N[13C](N)=O XSQUKJJJFZCRTK-OUBTZVSYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 229940003630 [13c] urea Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000011587 gastric lymphoma Diseases 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
- A23C9/203—Dietetic milk products not covered by groups A23C9/12 - A23C9/18 containing bifidus-active substances, e.g. lactulose; containing oligosaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
- A23C9/206—Colostrum; Human milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a solid beverage for inhibiting activity of helicobacter pylori, which relates to the field of food and comprises the following raw materials in percentage by weight: 48-53% of whole milk powder, 15-18% of bovine colostrum, 8-12% of xylo-oligosaccharide, 8-12% of galacto-oligosaccharide, 5-8% of fructo-oligosaccharide, 1-3% of lactitol, 1-3% of calcium aspartate, 0.5-1% of composite probiotics, 0.1-0.3% of selenium-enriched shepherd's purse powder and 0.3-0.6% of silicon dioxide. The solid beverage disclosed by the invention has good positive-negative conversion effect on patients carrying helicobacter pylori by adding the composite probiotics, the selenium-rich capsella bursa-pastoris powder and other raw materials, is suitable for children of 8 to 16 years old and old people with weak constitution, safely reduces the toxic and side effects caused by removing the helicobacter pylori by the existing triple and quadruple therapy, and improves the eradication rate.
Description
Technical Field
The invention relates to the technical field of food, in particular to a solid beverage for inhibiting activity of helicobacter pylori.
Background
The micro-ecology is closely related to human development, immunity and metabolism, and is influenced by genetics, environment, diet, living habits, age, etc., especially drastic changes occurring under disease conditions. How to regulate the micro-ecology has become an important scientific research and industrial direction from promoting health and preventing and treating diseases. The micro-ecological regulator is widely applied to industries such as medical treatment, health care, food, agriculture, animal husbandry, aquatic products and the like. At present, the application of the microecologics to treat various diseases has already achieved primary results, and has wide application prospects. In the future, technologies such as metabonomics and metagenomics and microecology research need to be more closely combined, and the influence of intestinal microecology on the occurrence, development and outcome of diseases is deeply understood so as to facilitate screening.
Helicobacter pylori is a spiral, gram-negative, microaerophilic bacterium. Almost half of all people have life-long infection, and the affected parts are mainly in the stomach and duodenal bulb. Helicobacter pylori parasitizes in gastric mucosal tissues and is an important pathogenic factor for diseases such as gastritis, peptic ulcer, lymphoproliferative gastric lymphoma and the like. The poor prognosis of H.pylori infection is gastric cancer, so that high attention is often paid to people. The helicobacter pylori infection rate is very high in the population of China, and the population base of the helicobacter pylori infection is very large. Currently, the drug resistance rate of helicobacter pylori to some common antibiotics is high, so that the eradication rate is reduced, and the reinfection rate can be higher after the helicobacter pylori is eradicated. The problem of eradication of H.pylori by non-compliant application of antibiotics, including non-compliant treatment, is particularly acute.
With the annual decline of the eradication rate of helicobacter pylori by the clinical triple and quadruple method, we are compelled to search for new therapies. The Masterz consensus regarding the management of H.pylori infection has suggested that eradication of H.pylori may compromise the normal gastrointestinal microbiota leading to short-term clinical consequences, and that eradication of H.pylori in order to avoid long-term clinical consequences is prudent in gastrointestinal microecological immaturity (infants) or in unstable persons (elderly, immunodeficient patients, etc.).
A random control study discusses the effects of synbiotics added in triple therapy on eradicating helicobacter pylori in children, relieving dyspepsia symptoms and reducing adverse antibiotic reactions. The results also show that the triple therapy and synbiotics are effective in treating the infantile helicobacter pylori infection and are helpful for relieving or eliminating dyspepsia symptoms such as abdominal pain, diarrhea, vomiting and the like. The antibiotics are not recommended to be taken in large amount for the infection of helicobacter pylori in children of 8 to 16 years old, and the antibiotics cannot be used for treating the liver and kidney injury of old people with weak constitution. The invention safely reduces the toxic and side effects caused by eliminating the helicobacter pylori by the existing triple and quadruple therapy and improves the eradication rate through a food-grade microecological regulation preparation formulation. The formula of the solid beverage belongs to the unique formula proportion of traditional Chinese Kodho, and after the inventor and volunteers eat the solid beverage for a period of time, the data before eating and after eating are compared through an expiration test (C13), so that the result of the detection of the patient carrying helicobacter pylori is obtained from positive to negative.
Disclosure of Invention
The invention aims to provide a solid beverage for inhibiting the activity of helicobacter pylori, which solves the following technical problems: the eradication rate of the helicobacter pylori by the existing clinical triple and quadruple method is reduced year by year, and the helicobacter pylori has drug resistance to antibiotics.
The purpose of the invention can be realized by the following technical scheme:
a solid beverage for inhibiting the activity of helicobacter pylori comprises the following raw materials in percentage by weight: 48-53% of whole milk powder, 15-18% of bovine colostrum, 8-12% of xylo-oligosaccharide, 8-12% of galacto-oligosaccharide, 5-8% of fructo-oligosaccharide, 1-3% of lactitol, 1-3% of calcium aspartate, 0.5-1% of composite probiotics, 0.1-0.3% of selenium-enriched shepherd's purse powder and 0.3-0.6% of silicon dioxide.
As a further scheme of the invention: comprises the following raw materials in percentage by weight: 50-52% of whole milk powder, 16-17% of bovine colostrum, 9-11% of xylo-oligosaccharide, 9-11% of galacto-oligosaccharide, 5-7% of fructo-oligosaccharide, 1-3% of lactitol, 1-3% of calcium aspartate, 0.5-1% of composite probiotics, 0.1-0.3% of selenium-enriched shepherdspurse herb powder and 0.4-0.6% of silicon dioxide.
As a further scheme of the invention: comprises the following raw materials in percentage by weight: 51.78% of full cream milk powder, 16.7% of bovine colostrum, 10% of xylo-oligosaccharide, 10% of galacto-oligosaccharide, 6% of fructo-oligosaccharide, 2% of lactitol, 2% of calcium aspartate, 0.85% of composite probiotics, 0.17% of selenium-enriched shepherd's purse powder and 0.5% of silicon dioxide.
As a further scheme of the invention: the preparation method of the selenium-rich shepherd's purse powder comprises the following steps:
(1) putting fresh selenium-rich shepherd's purse into color protection liquid for color protection;
(2) centrifugally dehydrating the shepherd's purse subjected to color protection treatment, and then carrying out vacuum freeze drying for 22-26h to obtain dried shepherd's purse;
(3) and (3) drying and crushing the shepherd's purse into powder to obtain the selenium-rich shepherd's purse powder.
As a further scheme of the invention: the color protection treatment is to soak the shepherd's purse in color protection solution obtained by mixing 2% sodium chloride aqueous solution and 0.2% sodium sulfate aqueous solution for 15-30 min.
As a further scheme of the invention: the compound probiotics are prepared by mixing lactobacillus plantarum CN2018, lactobacillus reuteri LR08, lactobacillus acidophilus LA85, bifidobacterium longum BL21, bifidobacterium lactis BLA80, lactobacillus casei LC89, lactobacillus plantarum LP90 and lactobacillus rhamnosus LRA05 in any ratio.
As a further scheme of the invention: the composite probiotics are prepared by mixing 5-10% of lactobacillus plantarum CN2018, 1-5% of lactobacillus reuteri LR08, 10-20% of lactobacillus acidophilus LA85, 10-20% of bifidobacterium longum BL21, 2-5% of bifidobacterium lactis BLA80, 20-30% of lactobacillus casei LC89, 10-15% of lactobacillus plantarum LP90 and 10-15% of lactobacillus rhamnosus LRA05 in percentage by weight.
As a further scheme of the invention: the preparation method of the solid beverage comprises the following steps:
(1) respectively placing the raw materials of the solid beverage into a grinder to be ground and sieved to obtain powder of each material;
(2) weighing and preparing the powder obtained in the step (1) according to the weight percentage;
(3) adding the powder obtained in the step (2) into a mixer to be uniformly mixed to obtain mixed powder;
(4) and (4) sieving the mixed powder obtained in the step (3), packaging and warehousing.
Advantageous effects
The invention provides a solid beverage for inhibiting the activity of helicobacter pylori. Compared with the prior art, the method has the following beneficial effects:
the solid beverage is prepared from whole milk powder, bovine colostrum, xylo-oligosaccharide, galacto-oligosaccharide, fructo-oligosaccharide, lactitol, calcium aspartate, composite probiotics, selenium-enriched shepherd's purse powder and silicon dioxide, wherein the added composite probiotics can effectively inhibit the growth of helicobacter pylori in vivo, reduce the gene expression level of helicobacter pylori virulence factors, inhibit the gene expression of urease Ure to reduce the ammonia production capacity of the helicobacter pylori, eradicate the helicobacter pylori on the gastric mucosa of a mouse and eliminate inflammation, and the rest components provide nutrition required by daily life for patients.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1:
a solid beverage for inhibiting the activity of helicobacter pylori comprises the following raw materials in percentage by weight: 53g of whole milk powder, 18g of bovine colostrum, 12g of xylo-oligosaccharide, 8g of galacto-oligosaccharide, 5g of fructo-oligosaccharide, 2g of lactitol, 1g of calcium aspartate, 0.5g of composite probiotics, 0.2g of selenium-enriched shepherd's purse powder and 0.3g of silicon dioxide.
The composite probiotics comprise 8 percent of lactobacillus plantarum CN2018 (the viable count is 8.0 multiplied by 10) in percentage by weight 10 CFU/g), 2% Roy's milk LR08 (viable count 8.0 × 10) 10 CFU/g), 15% Lactobacillus acidophilus LA85 (viable count 8.0X 10) 10 CFU/g), 17% Bifidobacterium longum BL21 (viable count 8.0X 10) 10 CFU/g), 3% Bifidobacterium lactis BLA80 (viable count 8.0 × 10) 10 CFUPerg), 25% Lactobacillus casei LC89 (viable count is 8.0X 10) 10 CFU/g), 15% Lactobacillus plantarum LP90 (viable count 8.0 × 10) 10 CFU/g), 15% Lactobacillus rhamnosus LRA05 (viable count 8.0 × 10) 10 CFU/g) are mixed.
The preparation method of the selenium-rich shepherd's purse powder comprises the following steps:
(1) putting fresh selenium-rich shepherd's purse into color protection liquid for color protection;
(2) mixing 2% sodium chloride water solution and 0.2% sodium sulfate water solution to obtain color protecting solution, soaking herba Capsellae in the color protecting solution for 30min, centrifuging, dehydrating, and vacuum freeze drying for 24 hr to obtain dried herba Capsellae;
(3) and (3) drying and crushing the shepherd's purse into powder to obtain the selenium-rich shepherd's purse powder.
The preparation method of the solid beverage comprises the following steps:
(1) respectively placing the raw materials of the solid beverage into a grinder to be ground and sieved to obtain powder of each material;
(2) weighing and preparing the powder obtained in the step (1) according to the weight percentage;
(3) adding the powder obtained in the step (2) into a mixer to be uniformly mixed to obtain mixed powder;
(4) and (4) sieving the mixed powder obtained in the step (3), packaging and warehousing.
Example 2:
a solid beverage for inhibiting the activity of helicobacter pylori comprises the following raw materials in percentage by weight: 53% of whole milk powder, 18% of bovine colostrum, 12% of xylo-oligosaccharide, 8% of galacto-oligosaccharide, 5% of fructo-oligosaccharide, 1% of lactitol, 2% of calcium aspartate, 0.6% of composite probiotics, 0.1% of selenium-enriched shepherd's purse powder and 0.3% of silicon dioxide.
The composite probiotics comprise 8 percent of lactobacillus plantarum CN2018 (the viable count is 8.0 multiplied by 10) in percentage by weight 10 CFU/g), 2% Roy's milk LR08 (viable count 8.0 × 10) 10 CFU/g), 15% Lactobacillus acidophilus LA85 (viable count 8.0 × 10) 10 CFU/g), 17% Bifidobacterium longum BL21 (viable count 8.0X 10) 10 CFU/g), 3% Bifidobacterium lactis BLA80 (viable count of 8.0 × 10) 10 CFU/g), 25% dryLactobacillus casei LC89 (viable count is 8.0 × 10) 10 CFU/g), 15% Lactobacillus plantarum LP90 (viable count 8.0 × 10) 10 CFU/g), 15% Lactobacillus rhamnosus LRA05 (viable count is 8.0 × 10) 10 CFU/g) are mixed.
The preparation method of the selenium-rich capsella bursa-pastoris powder is the same as that in the embodiment 1.
The preparation method of the solid beverage was identical to that in example 1.
Example 3:
a solid beverage for inhibiting the activity of helicobacter pylori comprises the following raw materials in percentage by weight: 53% of whole milk powder, 18% of bovine colostrum, 12% of xylo-oligosaccharide, 8% of galacto-oligosaccharide, 5% of fructo-oligosaccharide, 1% of lactitol, 2% of calcium aspartate, 0.5% of composite probiotics, 0.1% of selenium-enriched shepherd's purse powder and 0.4% of silicon dioxide.
The composite probiotics comprise 8 percent of lactobacillus plantarum CN2018 (the viable count is 8.0 multiplied by 10) by weight percentage 10 CFU/g), 2% Roy's milk straw LR08 (viable count 8.0X 10) 10 CFU/g), 15% Lactobacillus acidophilus LA85 (viable count 8.0X 10) 10 CFU/g), 17% Bifidobacterium longum BL21 (viable count 8.0X 10) 10 CFU/g), 3% Bifidobacterium lactis BLA80 (viable count 8.0 × 10) 10 CFU/g), 25% Lactobacillus casei LC89 (viable count is 8.0X 10) 10 CFU/g), 15% Lactobacillus plantarum LP90 (viable count 8.0X 10) 10 CFU/g), 15% Lactobacillus rhamnosus LRA05 (viable count 8.0 × 10) 10 CFU/g) are mixed.
The preparation method of the selenium-rich shepherd's purse powder is consistent with the preparation method in the embodiment 1.
The preparation method of the solid beverage was identical to that in example 1.
Example 4:
a solid beverage for inhibiting the activity of helicobacter pylori comprises the following raw materials in percentage by weight: 53% of whole milk powder, 18% of bovine colostrum, 12% of xylo-oligosaccharide, 8% of galacto-oligosaccharide, 5% of fructo-oligosaccharide, 1% of lactitol, 1.5% of calcium aspartate, 0.8% of composite probiotics, 0.2% of shepherd's purse powder rich in selenium and 0.5% of silicon dioxide.
The composite probiotics comprise 8 percent of lactobacillus plantarum CN2018 (the viable count is 8.0 multiplied by 10) in percentage by weight 10 CFU/g), 2% Roy's milk LR08 (viable count 8.0 × 10) 10 CFU/g), 15% Lactobacillus acidophilus LA85 (viable count 8.0X 10) 10 CFU/g), 17% Bifidobacterium longum BL21 (viable count 8.0X 10) 10 CFU/g), 3% Bifidobacterium lactis BLA80 (viable count 8.0 × 10) 10 CFU/g), 25% Lactobacillus casei LC89 (viable count 8.0 × 10) 10 CFU/g), 15% Lactobacillus plantarum LP90 (viable count 8.0X 10) 10 CFU/g), 15% Lactobacillus rhamnosus LRA05 (viable count 8.0 × 10) 10 CFU/g) are mixed.
The preparation method of the selenium-rich shepherd's purse powder is consistent with the preparation method in the embodiment 1.
The preparation method of the solid beverage was identical to that in example 1.
Example 5:
a solid beverage for inhibiting the activity of helicobacter pylori comprises the following raw materials in percentage by weight: 53% of whole milk powder, 18% of bovine colostrum, 12% of xylo-oligosaccharide, 8% of galacto-oligosaccharide, 5% of fructo-oligosaccharide, 1% of lactitol, 1.5% of calcium aspartate, 0.9% of composite probiotics, 0.3% of shepherd's purse powder rich in selenium and 0.3% of silicon dioxide.
The composite probiotics comprise 8 percent of lactobacillus plantarum CN2018 (the viable count is 8.0 multiplied by 10) in percentage by weight 10 CFU/g), 2% Roy's milk LR08 (viable count 8.0 × 10) 10 CFU/g), 15% Lactobacillus acidophilus LA85 (viable count 8.0 × 10) 10 CFU/g), 17% Bifidobacterium longum BL21 (viable count 8.0X 10) 10 CFU/g), 3% Bifidobacterium lactis BLA80 (viable count of 8.0 × 10) 10 CFU/g), 25% Lactobacillus casei LC89 (viable count 8.0 × 10) 10 CFU/g), 15% Lactobacillus plantarum LP90 (viable count 8.0X 10) 10 CFU/g), 15% Lactobacillus rhamnosus LRA05 (viable count 8.0 × 10) 10 CFU/g) are mixed.
The preparation method of the selenium-rich capsella bursa-pastoris powder is the same as that in the embodiment 1.
The preparation method of the solid beverage was identical to that in example 1.
And (3) performance detection:
100 H.pylori-positive patients were divided into five groups and each of the solid beverages (12g) prepared in examples 1 to 5 was taken daily. Detection of changes in H.pylori using the 13C-Urea breath test: the patient holds breath for 15s, half of the gas is discharged, and the other part of the gas is blown into the gas collecting bag, which is called as zero breath; after taking the medicine for four weeks, collecting the exhaled gas, wherein the exhaled gas is the sample gas, detecting the sample gas by using an infrared spectrometer, and recording the detection result.
And (3) judging the DOB value: 13C-CO measured in 30min sample gas 2 The difference between the δ permillage values of the δ permillage breath samples at zero subtracted by δ permillage: DOB ═ δ ‰ (28d) - δ ‰ (0 d);
DOB-4.0% is negative (-), DOB 4% -10% is light positive (+), DOB 10% -20% is medium positive (+ +), DOB 20% is strong positive (+ ++). The results are shown in Table 1.
Table 1:
as shown in Table 1, the solid beverage prepared by the invention can safely reduce the toxic and side effects caused by the removal of helicobacter pylori by the existing triple and quadruple therapy and effectively improve the eradication rate of the helicobacter pylori.
While one embodiment of the present invention has been described in detail, the description is only a preferred embodiment of the present invention and should not be taken as limiting the scope of the invention. All equivalent changes and modifications made within the scope of the present invention shall fall within the scope of the present invention.
Claims (8)
1. The solid beverage for inhibiting the activity of the helicobacter pylori is characterized by comprising the following raw materials in percentage by weight: 48-53% of whole milk powder, 15-18% of bovine colostrum, 8-12% of xylo-oligosaccharide, 8-12% of galacto-oligosaccharide, 5-8% of fructo-oligosaccharide, 1-3% of lactitol, 1-3% of calcium aspartate, 0.5-1% of composite probiotics, 0.1-0.3% of selenium-enriched shepherdspurse herb powder and 0.3-0.6% of silicon dioxide.
2. The solid beverage for inhibiting the activity of helicobacter pylori according to claim 1, which comprises the following raw materials in percentage by weight: 50-52% of whole milk powder, 16-17% of bovine colostrum, 9-11% of xylo-oligosaccharide, 9-11% of galacto-oligosaccharide, 5-7% of fructo-oligosaccharide, 1-3% of lactitol, 1-3% of calcium aspartate, 0.5-1% of composite probiotics, 0.1-0.3% of selenium-enriched shepherdspurse herb powder and 0.4-0.6% of silicon dioxide.
3. The solid beverage for inhibiting the activity of helicobacter pylori according to claim 1, which comprises the following raw materials in percentage by weight: 51.78% of full cream milk powder, 16.7% of bovine colostrum, 10% of xylo-oligosaccharide, 10% of galacto-oligosaccharide, 6% of fructo-oligosaccharide, 2% of lactitol, 2% of calcium aspartate, 0.85% of composite probiotics, 0.17% of selenium-enriched shepherd's purse powder and 0.5% of silicon dioxide.
4. The solid beverage for inhibiting the activity of helicobacter pylori according to claim 1, wherein the preparation method of the selenium-rich capsella bursa-pastoris powder comprises the following steps:
(1) putting fresh selenium-rich shepherd's purse into color protection liquid for color protection;
(2) centrifugally dewatering the shepherd's purse subjected to color protection treatment, and then carrying out vacuum freeze drying for 22-26h to obtain dried shepherd's purse;
(3) and (3) drying and crushing the shepherd's purse into powder to obtain the selenium-rich shepherd's purse powder.
5. The solid beverage for inhibiting the activity of helicobacter pylori according to claim 4, wherein the color protection treatment is to soak the shepherd's purse in a color protection solution obtained by mixing 2-5% of sodium chloride aqueous solution and 0.2-0.5% of sodium sulfate aqueous solution for 15-30 min.
6. The solid beverage for inhibiting the activity of helicobacter pylori according to claim 1, wherein the complex probiotics are obtained by mixing lactobacillus plantarum CN2018, lactobacillus reuteri LR08, lactobacillus acidophilus LA85, bifidobacterium longum BL21, bifidobacterium lactis BLA80, lactobacillus casei LC89, lactobacillus plantarum LP90, lactobacillus rhamnosus LRA05 in any ratio.
7. The solid beverage for inhibiting the activity of helicobacter pylori according to claim 6, wherein the composite probiotics are prepared by mixing, by weight, 5-10% of Lactobacillus plantarum CN2018, 1-5% of Lactobacillus reuteri LR08, 10-20% of Lactobacillus acidophilus LA85, 10-20% of Bifidobacterium longum BL21, 2-5% of Bifidobacterium lactis BLA80, 20-30% of Lactobacillus casei LC89, 10-15% of Lactobacillus plantarum LP90 and 10-15% of Lactobacillus rhamnosus LRA 05.
8. The solid beverage for inhibiting the activity of helicobacter pylori according to claim 1, wherein the preparation method of the solid beverage comprises the following steps:
(1) respectively placing the raw materials of the solid beverage into a grinder to be ground and sieved to obtain powder of each material;
(2) weighing and preparing the powder obtained in the step (1) according to the weight percentage;
(3) adding the powder obtained in the step (2) into a mixer to be uniformly mixed to obtain mixed powder;
(4) and (4) sieving the mixed powder obtained in the step (3), packaging and warehousing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210433316.4A CN114916584A (en) | 2022-04-24 | 2022-04-24 | Solid beverage for inhibiting activity of helicobacter pylori |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210433316.4A CN114916584A (en) | 2022-04-24 | 2022-04-24 | Solid beverage for inhibiting activity of helicobacter pylori |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114916584A true CN114916584A (en) | 2022-08-19 |
Family
ID=82807280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210433316.4A Pending CN114916584A (en) | 2022-04-24 | 2022-04-24 | Solid beverage for inhibiting activity of helicobacter pylori |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114916584A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115487220A (en) * | 2022-09-14 | 2022-12-20 | 上海菌小宝健康科技有限公司 | Compound probiotic powder for reducing helicobacter pylori and preparation method thereof |
| CN116236511A (en) * | 2023-05-09 | 2023-06-09 | 北京科拓恒通生物技术股份有限公司 | Metagen composition and application thereof in preparation of helicobacter pylori inhibiting products |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107594279A (en) * | 2017-09-29 | 2018-01-19 | 武汉华士特工业生物技术开发有限公司 | A kind of probiotic powder solid beverage and preparation method thereof |
| CN108041169A (en) * | 2017-11-29 | 2018-05-18 | 上海晨冠乳业有限公司 | A kind of children's solid beverage containing probiotics and prebiotics and preparation method thereof |
| CN108741090A (en) * | 2018-08-28 | 2018-11-06 | 安徽谷益生物科技有限公司 | A kind of compound probiotic functional food inhibiting helicobacter pylori |
| CN112914103A (en) * | 2021-02-22 | 2021-06-08 | 漯河微康生物科技有限公司 | Probiotic composition for resisting helicobacter pylori infection and application thereof |
-
2022
- 2022-04-24 CN CN202210433316.4A patent/CN114916584A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107594279A (en) * | 2017-09-29 | 2018-01-19 | 武汉华士特工业生物技术开发有限公司 | A kind of probiotic powder solid beverage and preparation method thereof |
| CN108041169A (en) * | 2017-11-29 | 2018-05-18 | 上海晨冠乳业有限公司 | A kind of children's solid beverage containing probiotics and prebiotics and preparation method thereof |
| CN108741090A (en) * | 2018-08-28 | 2018-11-06 | 安徽谷益生物科技有限公司 | A kind of compound probiotic functional food inhibiting helicobacter pylori |
| CN112914103A (en) * | 2021-02-22 | 2021-06-08 | 漯河微康生物科技有限公司 | Probiotic composition for resisting helicobacter pylori infection and application thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115487220A (en) * | 2022-09-14 | 2022-12-20 | 上海菌小宝健康科技有限公司 | Compound probiotic powder for reducing helicobacter pylori and preparation method thereof |
| CN116236511A (en) * | 2023-05-09 | 2023-06-09 | 北京科拓恒通生物技术股份有限公司 | Metagen composition and application thereof in preparation of helicobacter pylori inhibiting products |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105146614B (en) | A kind of functional calcium fruit ferment, enzyme beverage and its production method | |
| JP4623896B2 (en) | Bacterial strains, processed plant extracts and probiotic compositions used in humans and animals | |
| WO2007140621A1 (en) | Probiotic compositions and uses thereof | |
| WO2007140622A1 (en) | Dairy-derived probiotic compositions and uses thereof | |
| CN114916584A (en) | Solid beverage for inhibiting activity of helicobacter pylori | |
| CN111035014A (en) | Probiotic preparation and preparation method thereof | |
| CN111671079A (en) | Composite probiotic powder composition and preparation method thereof | |
| CN110338402A (en) | A kind of compound probiotic powder and preparation method thereof | |
| CN115074298A (en) | Probiotic composition with effects of resisting claustrophobia, protecting stomach and promoting digestion and eliminating stagnation and application thereof | |
| CN108850397A (en) | A kind of probiotic gel candy and preparation method thereof of only diarrhea | |
| US20220143114A1 (en) | Active substance of lactobacillus plantarum gkm3, a composition comprising thereof and its use for promoting longevity | |
| CN108904546A (en) | A kind of pair of helicobacter pylori has inhibition, the probiotic combinations preparation of killing effect and preparation method thereof | |
| CN109349644A (en) | Probiotic composition, health food and its preparation method and application | |
| CN113577218A (en) | Inactivated probiotic traditional Chinese medicine composition for inhibiting helicobacter pylori and preparation method and application thereof | |
| CN115838676A (en) | Traditional Chinese medicine fermentation by using novel lactobacillus plantarum strain and application | |
| CN114287633B (en) | Probiotic composition containing cranberry and application thereof in helicobacter pylori resistance | |
| CN109432136A (en) | A kind of probiotic combinations preparation and its preparation method and application | |
| CN107647410A (en) | A kind of probiotic powder of compound proportioning and preparation method thereof | |
| CN110313599A (en) | A kind of anti-trioxypurine jelly and preparation method thereof | |
| RU2577994C1 (en) | Reuterin-producing lactobacillus brevis | |
| JP2003252770A (en) | Agent for prevention, improvement and treatment of diabetic complication | |
| CN105663650A (en) | Probiotic fermentation traditional Chinese medicine composition for treating lung cancer and preparing method thereof | |
| CN115011513A (en) | Lactic acid bacteria powder for enhancing immunity, regulating intestines and stomach to control fat, losing weight and expelling toxin | |
| CN114984065A (en) | Probiotic composition for improving immunity and preparation method thereof | |
| CN112704234A (en) | Nutritional composition containing composite peptide and probiotics and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |